Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Inappropriate Disposal of Waste Material Containing Gene Recombinants Reported by Ono
August 9, 2010
- 7 New Drugs Recommended for Approval
August 9, 2010
- Shionogi to Begin PIII for Next-Generation HIV Drug by End 2010
August 9, 2010
- Kyowa Kirin's Sales in Jan.-June Up to ¥103,475 Mil. Driven by Nesp/Espo
August 9, 2010
- Greater-Strength Aricept Tab Approved in the US
August 9, 2010
- Dexrazoxane, Fomepizole to Be Developed
August 9, 2010
- Daiichi Sankyo, Kitasato Institute to Create Joint Venture for Vaccines
August 9, 2010
- Chuikyo to Discuss 1980 Notification in Earnest
August 9, 2010
- ASKA Aims at ¥50 Bil. Sales in Mid-Term Business Plan Starting FY2013
August 9, 2010
- Antiepileptic Drug E Keppra Approved: Otsuka, UCB
August 9, 2010
- Increases in Market Prices due to New Premium Not Touched by Council
August 9, 2010
- Yaz Approved for Dysmenorrhea: Bayer
August 9, 2010
- FPMAJ to Reduce CO2 Emissions by 23% in FY2020 vs FY2005
August 9, 2010
- Viviant Approved for Osteoporosis: Pfizer
August 9, 2010
- Nichi-Iko Ties Up with DKSH for Southeast Asian Market
August 9, 2010
- Forteo Approved for Osteoporosis: Eli Lilly
August 9, 2010
- AnGes MG Ties Up with EPS in China
August 9, 2010
- Volibris Approved for PAH: GSK
August 9, 2010
- Merck Ties Up with Sinopharm for Vaccine Business in China
August 9, 2010
- Onoact Approved for Improvement of Imaging Performance in CT-Based CAG
August 9, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…